Celiac HLA DQ Association

CPT: 81377(x2)

Synonyms

HLA DQ2; HLA DQ8; HLA Typing (DQ2, DQ8)


Special Instructions

If you have questions, please call HLA customer service at 800-533-1037 for assistance in selecting the appropriate HLA test for the patient.

Ship the specimen to arrive in the laboratory between Monday and Friday.


Expected Turnaround Time

3 - 7 days


Specimen Requirements


Specimen

Whole blood or buccal swabs


Volume

7 mL or four buccal swabs


Minimum Volume

3 mL or four buccal swabs


Container

Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). If submitting buccal swabs, please use the kit provided by Labcorp. To obtain the buccal swab kit or to discuss other specimen types, please call 800-533-1037.


Collection

Standard phlebotomy procedures or follow buccal swab kit instructions


Storage Instructions

Maintain specimen at room temperature. Protect from extreme heat or cold.


Stability Requirements

Temperature Period
Room temperature

Whole blood: >1 week

Buccal swabs: >2 years

FrozenWhole blood/DNA: indefinite

Causes for Rejection

Incorrect specimen container (tube type); yellow-top (ACD) tube


Test Details


Use

This test aids in the diagnosis of celiac disease. The HLA DQ Association test provides genotyping for detection of HLA-DQ2 (DQA1*05:01 or 05:05 and DQB1*02:01 or 02:02) and HLA-DQ8 (DQB1*03:02). Patients with DQ2, half DQ2 and/or DQ8 are predisposed to celiac disease. A negative result essentially rules out celiac disease. In addition to DQ2 and DQ8 status, the report also includes complete DQA and DQB genotypes, homozygosity for DQB1*02 and genetic risk assessment.

Celiac disease is an autoimmune disorder characterized by a well-defined genetic predisposition and sensitivity to gluten (found in wheat, barley and rye) that causes inflammation in the small intestine, villous atrophy and malabsorption. Celiac disease can present with gastrointestinal symptoms and/or widely variable non-gastrointestinal findings such as iron deficiency anemia, dermatitis herpetiformis, osteoporosis, chronic fatigue, short stature, neurologic symptoms and many more. Gastrointestinal symptoms are present in fewer than 50% of cases of systomatic celiac disease. Strict avoidance of gluten in the diet will rid inflammation in most cases, and celiac-associated antibodies are likely to disappear with time.

Celiac disease affects approximately one percent of the U.S. population, but only about 17% of cases are currently diagnosed. Underdiagnosis is likely due to the variable presentation of celiac disease and clinical overlap with numerous other disorders such as IBS. The prevalence of celiac disease in increased in certain autoimmune disorders such as insulin-dependent diabetes (~6%), thyroiditis (~2-4%) and Sjogren syndrome (~5%). It is also increased in Down syndrome (5-12%), Turner syndrome (~3%), Williams syndrome (3-10%) and selective IgA deficiency (~2-10%).

Genetic predisposition to celiac disease requires the presence of specific variants of the human leukocyte antigen (HLA) class II genes HLA-DQA1 and HLA-DQB1 to be present. These genes encode the alpha and beta chains of the celiac-associated proteins DQ2 and DQ8. Presence of DQ2, half DQ2 and/or DQ8 is required but not sufficient for the development of celiac disease. One or more of these HLA results are present in 30% of the population, but overall, only three percent of these individuals develop celiac disease. The risk for developing celiac disease increases when there is a first degree relative with celiac disease (e.g., the risk approaches 40% for siblings with the same HLA genotype as a patient with celiac disease).


Limitations

The HLA DQ Association test detects celiac disease-associated alleles that predispose to the disorder but is not diagnostic of celiac disease. More than 95% of celiac disease patients are positive for DQ2, half DQ2 or DQ8, but many individuals with these genetic results do not develop celiac disease. Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, fresh specimens should be collected for retesting.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Methodology

Next-generation sequencing or other methods as needed


References

Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007 Oct 25;357(17):1731-1743. PubMed 17960014

Pietzak MM, Schofield TC, McGinnis MJ, Nakamura RM. Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. Clin Gastroenterol Hepatol. 2009 Sep;7(9):966-971. PubMed 19500688

Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: Consensus on new nomenclature and classification. BMC Med. 2012 Feb 7:10:13. PubMed 22313950

Taylor AK, Lebwohl B, Snyder C, Green PHR. Celiac Disease. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993. [updated ]. PubMed 20301720


For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf